Biohaven Licenses Taldefgrobep Alfa, a Phase III-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb

Biohaven Pharmaceutical Holding Company Ltd. announced that it entered into a license agreement with Bristol Myers Squibb for the development and commercialization rights to taldefgrobep alfa, a novel, Phase III-ready anti-myostatin adnectin.